872 related articles for article (PubMed ID: 25440439)
1. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
2. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
5. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
7. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
8. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
9. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
Russo I; Zorzetto L; Frigo AC; Chiarion Sileni V; Alaibac M
Eur J Dermatol; 2017 Oct; 27(5):482-486. PubMed ID: 29084636
[TBL] [Abstract][Full Text] [Related]
12. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
13. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
14. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
15. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
[TBL] [Abstract][Full Text] [Related]
16. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
17. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
[TBL] [Abstract][Full Text] [Related]
18. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
20. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
